Self-adjuvanting bacterial vectors expressing pre-erythrocytic antigens induce sterile protection against malaria

Frontiers in Immunology

Volumn 4, Issue JUL, 2013, Pages

  Bergmann Leitner, Elke S ^a   Hosie, Heather ^a   Trichilo, Jessica ^b   DeRiso, Elizabeth ^a   Ranallo, Ryan T ^c,d   Alefantis, Timothy ^b,e   Savranskaya, Tatyana ^c   Grewal, Paul ^b   Ockenhouse, Christian F ^a   Venkatesan, Malabi M ^c   DelVecchio, Vito G ^b   Angov, Evelina ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b Vital Probes Inc   (United States)

^c WRAIR   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e Sanofi Pasteur Biologics Co   (United States)

Author keywords

Bacterial vaccine vector; Cellular targeting; CelTOS; CSP; E. coli; Malaria; Self adjuvanting; Shigella

Indexed keywords

ADJUVANT; BACTERIAL VECTOR; CIRCUMSPOROZOITE PROTEIN; ERYTHROCYTE ANTIGEN; ESCHERICHIA COLI VACCINE; GAMMA INTERFERON; INTERLEUKIN 4; MALARIA VACCINE; MALTOSE BINDING PROTEIN; OUTER MEMBRANE PROTEIN A; RECOMBINANT PROTEIN; SHIGELLA VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; BACTERIAL GENE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOSOL; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; ESCHERICHIA COLI; EXPRESSION VECTOR; FEMALE; FREEZE DRYING; GENE EXPRESSION; GENE INACTIVATION; IMMUNITY; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOGENICITY; MALARIA; MOUSE; NONHUMAN; OUTER MEMBRANE; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SHIGELLA FLEXNERI; SHIGELLOSIS; SPOROZOITE; TH1 CELL; TH2 CELL; VACCINATION; WESTERN BLOTTING;

EID: 84883694908     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00176     Document Type: Article

References (57)

1. Ben-Yedidia T, Arnon R. Design of peptide and polypeptide vaccines. Curr Opin Biotechnol (1997) 8:442-8.
2. Liljeqvist S, Stahl S. Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines. J Biotechnol (1999) 73:1-33.
3. Arnon R. Synthetic vaccines based on peptides, oligonucleotides and conjugate antigens. Behring Inst Mitt (1997) (98):184-90.
4. Hansson M, Nygren PA, Stahl S. Design and production of recombinant subunit vaccines. Biotechnol Appl Biochem (2000) 32(Pt 2):95-107.
5. Lesinski GB, Westerink MA. Vaccines against polysaccharide antigens. Curr Drug Targets Infect Disord (2001) 1:325-34.
6. Gilbert SC. T-cell-inducing vaccines-what's the future. Immunology (2012) 135:19-26.
7. Kotton CN, Hohmann EL. Enteric pathogens as vaccine vectors for foreign antigen delivery. Infect Immun (2004) 72:5535-47.
8. Clark TG, Cassidy-Hanley D. Recombinant subunit vaccines: potentials and constraints. Dev Biol Basel (2005) 121:153-63.
9. Detmer A, Glenting J. Live bacterial vaccines-a review and identification of potential hazards. Microb Cell Fact (2006) 5:23.
10. Tabrizi CA, Walcher P, Mayr UB, Stiedl T, Binder M, Mcgrath J, et al. Bacterial ghosts-biological particles as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol (2004) 15:530-7.
11. Moyle PM, Toth I. Modern subunit vaccines: development, components, and research opportunities. ChemMedChem (2013) 8(3):360-76.
12. Schijns VE, Lavelle EC. Trends in vaccine adjuvants. Expert Rev Vaccines (2011) 10:539-50.
13. Levitz SM, Golenbock DT. Beyond empiricism: informing vaccine development through innate immunity research. Cell (2012) 148:1284-92.
14. Leitner WW. Vaccine adjuvants: is the pipeline clogged?. Immunotherapy (2012) 4:565-7.
15. Medzhitov R, Janeway CA Jr. Decoding the patterns of self and nonself by the innate immune system. Science (2002) 296:298-300.
16. Bergmann-Leitner ES, Leitner WW, Tsokos GC. Complement 3d: from molecular adjuvant to target of immune escape mechanisms. Clin Immunol (2006) 121:177-85.
17. Mongini PK, Tolani S, Fattah RJ, Inman JK. Antigen receptor triggered upregulation of CD86 and CD80 in human B cells: augmenting role of the CD21/CD19 costimulatory complex and Il-4. Cell Immunol (2002) 216:50-64.
18. Hjelm F, Carlsson F, Getahun A, Heyman B. Antibody-mediated regulation of the immune response. Scand J Immunol (2006) 64:177-84.
19. EL Shikh ME, EL Sayed RM, Sukumar S, Szakal AK, Tew JG. Activation of B cells by antigens on follicular dendritic cells. Trends Immunol (2010) 31:205-11.
20. Wu Y, Sukumar S, EL Shikh ME, Best AM, Szakal AK, Tew JG. Immune complex-bearing follicular dendritic cells deliver a late antigenic signal that promotes somatic hypermutation. J Immunol (2008) 180:281-90.
21. Aydar Y, Sukumar S, Szakal AK, Tew JG. The influence of immune complex-bearing follicular dendritic cells on the IgM response, Ig class switching, and production of high affinity IgG. J Immunol (2005) 174:5358-66.
22. Germanier R, Fuer E. Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J Infect Dis (1975) 131:553-8.
23. Sztein MB. Cell-mediated immunity and antibody responses elicited by attenuated Salmonella enterica Serovar Typhi strains used as live oral vaccines in humans. Clin Infect Dis (2007) 45(Suppl 1):S15-9.
24. Lagos R, San Martin O, Wasserman SS, Prado V, Losonsky GA, Bustamante C, et al. Palatability, reactogenicity and immunogenicity of engineered live oral cholera vaccine CVD 103-HgR in Chilean infants and toddlers. Pediatr Infect Dis J (1999) 18:624-30.
25. Taylor DN, Sanchez JL, Castro JM, Lebron C, Parrado CM, Johnson DE, et al. Expanded safety and immunogenicity of a bivalent, oral, attenuated cholera vaccine, CVD 103-HgR plus CVD 111, in United States military personnel stationed in Panama. Infect Immun (1999) 67:2030-4.
26. Checkley AM, Mcshane H. Tuberculosis vaccines: progress and challenges. Trends Pharmacol Sci (2011) 32:601-6.
27. Mcshane H. Tuberculosis vaccines: beyond bacille Calmette-Guerin. Philos Trans R Soc Lond B Biol Sci (2011) 366:2782-9.
28. Roland KL, Tinge SA, Killeen KP, Kochi SK. Recent advances in the development of live, attenuated bacterial vectors. Curr Opin Mol Ther (2005) 7:62-72.
29. Collins TA, Barnoy S, Baqar S, Ranallo RT, Nemelka KW, Venkatesan MM. Safety and colonization of two novel VirG(IcsA)-based live Shigella sonnei vaccine strains in rhesus macaques (Macaca mulatta). Comp Med (2008) 58:88-94.
30. Mckenzie R, Venkatesan MM, Wolf MK, Islam D, Grahek S, Jones AM, et al. Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidate. Vaccine (2008) 26:3291-6.
31. Kaminski RW, Oaks EV. Inactivated and subunit vaccines to prevent shigellosis. Expert Rev Vaccines (2009) 8:1693-704.
32. Ranallo RT, Fonseka S, Boren TL, Bedford LA, Kaminski RW, Thakkar S, et al. Two live attenuated Shigella flexneri 2a strains WRSf2G12 and WRSf2G15: a new combination of gene deletions for 2nd generation live attenuated vaccine candidates. Vaccine (2012) 30:5159-71.
33. Simon JK, Maciel M Jr., Weld ED, Wahid R, Pasetti MF, Picking WL, et al. Antigen-specific IgA B memory cell responses to Shigella antigens elicited in volunteers immunized with live attenuated Shigella flexneri 2a oral vaccine candidates. Clin Immunol (2011) 139:185-92.
34. Tartz S, Russmann H, Kamanova J, Sebo P, Sturm A, Heussler V, et al. Complete protection against P. berghei malaria upon heterologous prime/boost immunization against circumsporozoite protein employing Salmonella type III secretion system and Bordetella adenylate cyclase toxoid. Vaccine (2008) 26:5935-43.
35. Nganou-Makamdop K, Van Roosmalen ML, Audouy SA, Van Gemert GJ, Leenhouts K, Hermsen CC, et al. Bacterium-like particles as multi-epitope delivery platform for Plasmodium berghei circumsporozoite protein induce complete protection against malaria in mice. Malar J (2012) 11:50.
36. Jiang S, Rasmussen RA, Nolan KM, Frankel FR, Lieberman J, Mcclure HM, et al. Live attenuated Listeria monocytogenes expressing HIV Gag: immunogenicity in rhesus monkeys. Vaccine (2007) 25:7470-9.
37. Loeffler DI, Schoen CU, Goebel W, Pilgrim S. Comparison of different live vaccine strategies in vivo for delivery of protein antigen or antigen-encoding DNA and mRNA by virulence-attenuated Listeria monocytogenes. Infect Immun (2006) 74:3946-57.
38. Cranage MP, Mcbride BW, Rud EW. The simian immunodeficiency virus transmembrane protein is poorly immunogenic in inactivated virus vaccine. Vaccine (1995) 13:895-900.
39. Rossio JL, Esser MT, Suryanarayana K, Schneider DK, Bess JW Jr., Vasquez GM, et al. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J Virol (1998) 72:7992-8001.
40. Eko FO, Witte A, Huter V, Kuen B, Furst-Ladani S, Haslberger A, et al. New strategies for combination vaccines based on the extended recombinant bacterial ghost system. Vaccine (1999) 17:1643-9.
41. Langemann T, Koller VJ, Muhammad A, Kudela P, Mayr UB, Lubitz W. The Bacterial Ghost platform system: production and applications. Bioeng Bugs (2010) 1:326-36.
42. Fennelly GJ, Khan SA, Abadi MA, Wild TF, Bloom BR. Mucosal DNA vaccine immunization against measles with a highly attenuated Shigella flexneri vector. J Immunol (1999) 162:1603-10.
43. Angov E, Hillier CJ, Kincaid RL, Lyon JA. Heterologous protein expression is enhanced by harmonizing the codon usage frequencies of the target gene with those of the expression host. PLoS ONE (2008) 3:e2189.
44. Bergmann-Leitner ES, Legler PM, Savranskaya T, Ockenhouse CF, Angov E. Cellular and humoral immune effector mechanisms required for sterile protection against sporozoite challenge induced with the novel malaria vaccine candidate CelTOS. Vaccine (2011) 29:5940-9.
45. Bergmann-Leitner ES, Mease RM, DE LA, Vega P, Savranskaya T, Polhemus M, et al. Immunization with pre-erythrocytic antigen CelTOS from Plasmodium falciparum elicits cross-species protection against heterologous challenge with Plasmodium berghei. PLoS ONE (2010) 5:e12294.
46. Tewari R, Spaccapelo R, Bistoni F, Holder AA, Crisanti A. Function of region I and II adhesive motifs of Plasmodium falciparum circumsporozoite protein in sporozoite motility and infectivity. J Biol Chem (2002) 277:47613-8.
47. Leitner WW, Bergmann-Leitner ES, Angov E. Comparison of Plasmodium berghei challenge models for the evaluation of pre-erythrocytic malaria vaccines and their effect on perceived vaccine efficacy. Malar J (2010) 9:145.
48. Bergmann-Leitner ES, Scheiblhofer S, Weiss R, Duncan EH, Leitner WW, Chen D, et al. C3d binding to the circumsporozoite protein carboxy-terminus deviates immunity against malaria. Int Immunol (2005) 17:245-55.
49. Migliorini P, Betschart B, Corradin G. Malaria vaccine: immunization of mice with a synthetic T cell helper epitope alone leads to protective immunity. Eur J Immunol (1993) 23:582-5.
50. Leitner WW, Ying H, Restifo NP. DNA and RNA-based vaccines: principles, progress and prospects. Vaccine (1999) 18:765-77.
51. Romero PJ, Tam JP, Schlesinger D, Clavijo P, Gibson H, Barr PJ, et al. Multiple T helper cell epitopes of the circumsporozoite protein of Plasmodium berghei. Eur J Immunol (1988) 18:1951-7.
52. Romero P, Corradin G, Luescher IF, Maryanski JL. H-2Kd-restricted antigenic peptides share a simple binding motif. J Exp Med (1991) 174:603-12.
53. Ranallo RT, Thakkar S, Chen Q, Venkatesan MM. Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain. Vaccine (2007) 25:2269-78.
54. Venkatesan MM, Ranallo RT. Live-attenuated Shigella vaccines. Expert Rev Vaccines (2006) 5:669-86.
55. Sizemore DR, Branstrom AA, SadoffJC. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science (1995) 270:299-302.
56. Mader HJ, Szostak MP, Hensel A, Lubitz W, Haslberger AG. Endotoxicity does not limit the use of bacterial ghosts as candidate vaccines. Vaccine (1997) 15:195-202.
57. Vanderberg J, Mueller AK, Heiss K, Goetz K, Matuschewski K, Deckert M, et al. Assessment of antibody protection against malaria sporozoites must be done by mosquito injection of sporozoites. Am J Pathol (2007) 171:1405-6. author reply 1406.